Residual cardiac risk reduction beyond lipid lowering

Hellenic Journal of Cardiology

Volumn 52, Issue 3, 2011, Pages 197-203

  Gossios, Thomas D ^a   Tziomalos, Konstantinos ^a   Karagiannis, Asterios ^a   Geleris, Paraschos ^a   Athyros, Vasilios G ^a   Pagourelias, Efstathios D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DOCOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN; STATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC CARDIOMYOPATHY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; RISK REDUCTION; SUDDEN DEATH;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 79959351630     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Fruchart J-C, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102: 1K-34K
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352: 1425-1435.
3. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005; 5: 379-387.
4. Fruchart JC, Sacks F, Hermans MP, et al. Residual Risk Reduction Initiative (R3I): The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008; 5: 319-335.
5. Majmudar MD, Tompkins C, Bachmann JM, Blumenthal RS, Marine JE. Effects of lipid-altering therapies on ventricular arrhythmias and sudden cardiac death. Cardiol Rev. 2009; 17: 60-69.
6. Beri A, Contractor T, Khasnis A, Thakur R. Statins and the reduction of sudden cardiac death: antiarrhythmic or antiischemic effect? Am J Cardiovasc Drugs. 2010; 10: 155-164.
7. Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J. 1989; 117: 151-159.
8. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001; 345: 1473-1482.
9. Gazi I, Liberopoulos EN, Saougos VG, Elisaf M. Beneficial effects of omega-3 fatty acids: the current evidence. Hellenic J Cardiol. 2006; 47: 223-231.
10. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999; 354 447-455.
11. Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-1098.
12. Matsuzaki M, Yokoyama M, Saito Y, et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J.2009; 73: 1283-1290.
13. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008; 200: 135-140.
14. Ishikawa Y, Yokoyama M, Saito Y, et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circ J. 2010; 74: 1451-1457.
15. Tziomalos K, Athyros VG, Mikhailidis DP. Fish oils and vascular disease prevention: an update. Curr Med Chem. 2007;14: 2622-2628.
16. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003; 23: e20-30.
17. Kromhout D, Giltay EJ, Geleijnse JM; for the Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010; 363: 2015-2026
18. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006; 296: 1885-1899.
19. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 1223-1230.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002; 360: 7-22.
21. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.Lancet. 2008; 372: 1231-1239.
22. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of therosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol. 2005; 96: 61F-68F.
23. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP. Early statin therapy in patients with acute coronary syndrome. Hellenic J Cardiol. 2005; 46: 5-8.
24. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest. 2005; 115: 2305-2315.
25. Dułak E, Lubiński A, Bissinger A, et al. Recurrence of ventricular arrhythmias in patients with non-ischaemic dilated cardiomyopathy: evidence-based predictors. Kardiol Pol. 2009; 67: 837-844.
26. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489-497.
27. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarctionand reduced ejection raction. N Engl J Med. 2002; 346: 877-883.
28. Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006; 26: 85S-97S.
29. Abuissa H, O'Keefe JH, Bybee KA. Statins as anti-arrhythmics: a systematic review part II: effects on risk of ventricular arrhythmias. Clin Cardiol. 2009; 32: 549-552.
30. Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006; 47: 769-773.
31. Goldberger JJ, Subacius H, Schaechter A, et al. effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006; 48: 1228-1233.
32. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007; 153: 573-578.
33. Levantesi G, Scarano M, Marfisi RM, et al. Meta-analysis of effect of statin treatment on risk of sudden death. Am J Cardiol. 2007; 100: 1644-1650.
34. Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant. 2007; 22: 963-964.
35. Riahi S, Schmidt EB, Christensen JH, et al. Statins, ventricular arrhythmias and heart rate variability in patients with implantable cardioverter defibrillators and coronary heart disease. Cardiology. 2005; 104: 210-214.
36. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hyper cholesterolaemic patients with or without coronary artery disease. Atherosclerosis. 2001; 157: 463-469.
37. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail. 2005; 11: 684-690.
38. Gentlesk PJ, Wiley T, Taylor AJ. A prospective evaluation of the effect of simvastatin on heart rate variability in non-ischemic cardiomyopathy. Am Heart J. 2005; 150: 478-483.
39. Mark L, Katona A. Effect of fluvastatin on QT dispersion: a new pleiotropic effect? Am J Cardiol. 2000; 85: 919-920.
40. Anastasakis A, McKenna W, Stefanadis C. Prevention of sudden cardiac death in the young: targeted evaluation of those at risk. Hellenic J Cardiol. 2006; 47: 251-254.
41. Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005; 96:1699-1704.
42. Psychari SN, Apostolou TS, Iliodromitis EK, Kourakos P, Liakos G, Kremastinos DT. Inverse relation of C-reactive protein levels to heart rate variability in patients after acute myocardial infarction. Hellenic J Cardiol. 2007; 48: 64-71.
43. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009; 15: MS12-23.
44. Abuissa H, O'Keefe JH, Bybee KA. Statins as antiarrhythmics:a systematic review part I: effects on risk of atrial fibrillation. Clin Cardiol. 2009; 32: 544-548.
45. Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol. 2006; 47: 51-53.
46. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003; 92: 1379-1383.
47. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006; 3: 881-886.
48. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006; 114: 1455-1461.
49. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2006; 97: 1490-1493.
50. Foody JAM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006; 113:1086-1092.
51. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006; 296: 2105-2111.
52. Lakoumentas JA, Dimitroula TG, Aggeli KA, Harbis PK. Cholesterol levels and the benefit of statins in heart failure. Hellenic J Cardiol. 2005; 46: 226-231.
53. Sankaranarayanan R, Maini S, James MA, Burtchaell S, Chatterjee AK. Do statins improve heart failure outcome in post-myocardial infarction patients with moderate to severe left ventricular dysfunction? Congest Heart Fail. 2010; 16:181-186.
54. Rosolova H, Cech J, Simon J, et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic-a report from the EuroHeart Failure Survey. Eur J Heart Fail. 2005; 7: 780-783.
55. Vrtovec B, Okrajsek R, Golicnik A, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008; 14: 140-144.
56. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357:2248-2261.
57. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. CORONA, statins, and heart failure: who lost the crown? Angiology. 2008; 59: 5-8.
58. Lipinski MJ, Cauthen CA, Biondi-Zoccai GGL, et al. Metaanalysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol. 2009; 104:1708-1716.
59. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin. 2002; 18: 220-228.
60. Athyros VG, Karagiannis A, Mikhailidis DP. Statins and heart failure. J Am Coll Cardiol. 2010; 55: 1644-1645.
61. FDA. Atorvastatin Calcium [Internet] [Accessed September 2010]. Available from: http://www.fda.gov/medwatch/ safety/2007/Sep_PI/ Lipitor_PI.pdf.
62. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007; 115: 576-583.
63. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004; 57:728-734.
64. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007; 22: 118-127.
65. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin. 2004; 20: 951-954.
66. Aksoy N, Ozer O, Sari I, Sucu M, Aksoy M, Geyikli I. Contribution of renal function impairment to unexplained troponin T elevations in congestive heart failure. Ren Fail. 2009;31: 272-277.